Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Ozette Technologies Receives $26M Series A

2022-07-28
SEATTLE, WA, Ozette Technologies today announced its $26 million Series A funding round.
Ozette Technologies, a technology-driven life sciences startup engineering a transformative leap in cell discovery and annotation of the human immune system, today announced its $26MM Series A funding, led by Madrona Ventures. Other participating investors include Cercano Management (formerly Vulcan Capital), M12, Microsoft's venture fund, Alexandria Venture Investments, OCV Partners and Duke University.

Ozette Technologies is engineering a transformative leap in cell discovery and annotation of the human immune system. The remote-first life sciences technology startup is building a groundbreaking high-resolution, intelligent, single-cell immune monitoring platform and corpus of high-resolution data leveraging its novel AI technologies. Founded in late 2020, Ozette was spun-out from the Fred Hutchinson Cancer Center and incubated at the Allen Institute for AI. Ozette's interdisciplinary team is made up of a deep bench of scientists, engineers, and designers with a wide range of experience spanning Genentech, Google, Microsoft, Amazon, Airbnb, and more. Ozette's team also includes leaders and pioneers in the field of medical research and single cell analysis, including its founders: physician Ali Ansary, and scientists Greg Finak, Evan Greene, and Raphael Gottardo.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors